UroGen Pharma
URGN· Manufacturing· Fiscal year ends in December
Elizabeth Barrett is the CEO of UroGen Pharma and was paid $4.3M in FY2025 (Dec), up 4%.
Executives3
See all- 1Elizabeth BarrettChief Executive OfficerFY2025
- 2Jason SmithGeneral Counsel and Chief Compliance OfficerFY2025
- 3Mark P. Schoenberg, M.D.Chief Medical OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allUroGen Pharma paid its 3 named executives $6.7M in total in FY2025 (Dec). CEO Elizabeth Barrett was paid $4.3M of that.
| Name | |||
|---|---|---|---|
| Elizabeth BarrettChief Executive Officer | |||
| Jason SmithGeneral Counsel and Chief Compliance Officer | |||
| Mark P. Schoenberg, M.D.Chief Medical Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers18
See allThe FY2025 (Dec) proxy of UroGen Pharma names 18 peer companies for pay. Among UroGen Pharma and these peers, CEO pay was 6th highest of 7 and total shareholder return was the highest of 6.
6th highest of 7in UroGen Pharma and its pay peers, FY2025 (Dec) by CEO pay:
1st highest of 6in UroGen Pharma and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board4
See all- Stuart Holden, M.D.Director · 10 yr on the boardIndependentAudit, Compliance—Paid as an executive
- Cynthia ButittaDirector · 8 yr on the boardIndependentAudit (Chair)—Paid as an executive
- Daniel G. WildmanDirector · 3 yr on the boardIndependentCompliance—Paid as an executive
- James A. Robinson, JrDirector · 2 yr on the boardIndependentCompliance (Chair)—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 30, 2026 | FY2025 |
| Annual report | 10-K | Mar 2, 2026 | FY2025 |
| Proxy statement | DEF 14A | Jul 15, 2025 | FY2024 |
| Annual report | 10-K | Mar 10, 2025 | FY2024 |
| Proxy statement | DEF 14A | Jul 1, 2024 | FY2023 |
| Annual report | 10-K | Mar 14, 2024 | FY2023 |